Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Finerenone

FDA-approved product (tablet, oral), marketed as Kerendia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Finerenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Nonsteroidal Mineralocorticoid-Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Finerenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Finerenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

    NCT01874431 · start 2013-06-12

    Registered record
    Registry ID
    NCT01874431
    Conditions
    Diabetic Nephropathies
    Interventions
    Finerenone (BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06-12
    Completion
    2014-08-07
    Enrolment
    823

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathies
    InterventionFinerenone (BAY94-8862); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

    NCT01687920 · start 2012-09-17

    Registered record
    Registry ID
    NCT01687920
    Conditions
    Heart Failure
    Interventions
    BAY94-8862 (1.25mg); BAY94-8862 (2.5mg); BAY94-8862 (5mg); BAY94-8862 (7.5mg); BAY94-8862 (10mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-09-17
    Completion
    2013-03-21
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionBAY94-8862 (1.25mg); BAY94-8862 (2.5mg); BAY94-8862 (5mg); BAY94-8862 (7.5mg) +1 more
    PhasePhase 1
    Registry statusCompleted

  • BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

    NCT01345656 · start 2011-05-09

    Registered record
    Registry ID
    NCT01345656
    Conditions
    Heart Failure
    Interventions
    BAY94-8862; BAY94-8862; BAY94-8862; BAY94-8862; Placebo; Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05-09
    Completion
    2012-07-16
    Enrolment
    457

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionBAY94-8862; BAY94-8862; BAY94-8862; BAY94-8862 +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

    NCT04908436 · start 2010-10-27

    Registered record
    Registry ID
    NCT04908436
    Conditions
    Worsening Chronic Heart Failure; Chronic Kidney Disease
    Interventions
    Finerenone (BAY94-8862)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10-27
    Completion
    2012-01-27
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWorsening Chronic Heart Failure; Chronic Kidney Disease
    InterventionFinerenone (BAY94-8862)
    PhasePhase 1
    Registry statusCompleted

  • Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

    NCT02378805 · start 1995-07

    Registered record
    Registry ID
    NCT02378805
    Conditions
    Alport Syndrome; Hereditary Kidney Disease; Pediatric Kidney Disease; Thin Basement Membrane Disease; Familial Benign Hematuria
    Interventions
    ACE-inhibitor; Angiotensin-receptor blocker (ARB); HMG-Coenzyme inhibitor (statin); Spironolactone or Finerenone; Paricalcitol; SGLT2 inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    1995-07
    Completion
    2036-03-01
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlport Syndrome; Hereditary Kidney Disease; Pediatric Kidney Disease; Thin Basement Membrane Disease +1 more
    InterventionACE-inhibitor; Angiotensin-receptor blocker (ARB); HMG-Coenzyme inhibitor (statin); Spironolactone or Finerenone +2 more
    PhaseNot recorded
    Registry statusRecruiting